Inovio pharmaceuticals stock.
Shares Outstanding: As of June 30, 2023, INOVIO had 268.1 million common shares outstanding and 290.0 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt ...
Inovio Pharmaceuticals, Inc. Common Stock (INO) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Lead Case No. 2:20-cv-01962-GJP. NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER. DERIVATIVE ACTIONS. TO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF INOVIO PHARMACEUTICALS, INC ...Inovio Pharmaceuticals (INO 1.39%) ... Notably, Inovio's stock skyrocketed once again at the end of April, when it announced that its vaccine candidate for MERS, another coronavirus, ...WebFind out the direct holders, institutional holders and mutual fund holders for Inovio Pharmaceuticals, Inc. (INO).INO | Complete Inovio Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
As of June 30, 2022, Inovio had 247.5 million shares of common stock outstanding and 267.8 million shares of common stock outstanding on a fully diluted basis. Total operating expenses were $104.9M.INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Commission (EC) has granted orphan drug designation for INO-3107, the company's product …Aug 9, 2022 · As of June 30, 2022, INOVIO had 247.5 million shares of common stock outstanding and 267.8 million shares of common stock outstanding on a fully diluted basis, after giving effect to the exercise, vesting and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt.
Inovio Pharmaceuticals. Market Cap. $111M. Today's Change. (2.77%) $0.01. Current Price. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may differ ...
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. About the company. INO fundamental analysis.Mar 1, 2023 · Inovio Pharmaceuticals, Inc. stockholders' equity: Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2022 and 2021 INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis. PR Newswire Sep 7, 2023 12:00pm.As of June 30, 2022, INOVIO had 247.5 million shares of common stock outstanding and 267.8 million shares of common stock outstanding on a fully diluted basis, after giving effect to the exercise, vesting and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt.
The average trading volume of INO on November 28, 2023 was 3.45M shares. INO) stock’s latest price update. Inovio Pharmaceuticals Inc (NASDAQ: INO)’s stock price has decreased by -3.07 compared to its previous closing price of 0.41. However, the company has seen a -5.38% decrease in its stock price over the last five trading sessions.
View Inovio Pharmaceuticals, Inc INO investment & stock information. Get the latest Inovio Pharmaceuticals, Inc INO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.
Inovio (INO) delivered earnings and revenue surprises of -14.29% and 42.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that data from a Phase 1b trial evaluating INO-4201 as an Ebola booster vaccine candidate for rVSV-ZEBOV (Ervebo) ( …The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large 27% drop over the last ten ...See Inovio Pharmaceuticals, Inc. (INO) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Finrange – is a stock analysis service for private investors. We create tools for investing that help to earn money in stock market spending less time for it.
The latest price target for Inovio Pharmaceuticals ( NASDAQ: INO) was reported by RBC Capital on Thursday, May 11, 2023. The analyst firm set a price target for 2.00 expecting INO to rise to ... Inovio (INO) delivered earnings and revenue surprises of -14.29% and 42.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?The biotech stock, still reeling from a failed clinical trial, hit a 52-week low. ... Shares of Inovio Pharmaceuticals (INO 4.20%) were down more than 10% on Tuesday afternoon, ...Sep. 7, 2023, 08:14 AM. (RTTNews) - Biotechnology company Inovio Pharmaceuticals, Inc. (INO) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy ...WebSee Inovio Pharmaceuticals, Inc. (INO) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.FDA Lifts Partial Clinical Hold on INNOVATE Phase 3 Segment INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced that the U.S. Food and Drug Administration …
Find real-time INO - Inovio Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business.WebThe Inovio Pharmaceuticals stock price gained 4.20% on the last trading day (Thursday, 30th Nov 2023), rising from $0.378 to $0.394.During the last trading day the stock fluctuated 6.38% from a day low at $0.371 to a day high of $0.395.The price has fallen in 6 of the last 10 days but is still up by 3.68% over the past 2 weeks. Volume fell on the …
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2023. Find the latest Inovio Pharmaceuticals ...INO stock trades near $10 currently and it is, in fact, down 27% from its pre-Covid high of around $14 in early March 2020 – before the coronavirus pandemic hit the world. INO stock has had a ...INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2023. Find the latest Inovio Pharmaceuticals ...Aug 9, 2022 · As of June 30, 2022, INOVIO had 247.5 million shares of common stock outstanding and 267.8 million shares of common stock outstanding on a fully diluted basis, after giving effect to the exercise, vesting and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt. Shares Outstanding: As of June 30, 2023, INOVIO had 268.1 million common shares outstanding and 290.0 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt.Mar 1, 2023 · The year-over-year increase in G&A expenses was primarily due to a $14.0 million non-cash expense related to the settlement of INOVIO's securities class action litigation, including the issuance of INOVIO common stock as part of the settlement, $14.3 million in higher legal expenses, primarily related to litigation matters, $6.9 million in one ... Holder Shares Date Reported % Out Value; Vanguard Total Stock Market Index Fund: 8,260,428: Jun 29, 2023: 3.03%: 3,221,566: Vanguard Horizon Fund-Strategic Small-Cap ...The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large 27% drop over the last ten ...
The Inovio Pharmaceuticals stock price gained 4.20% on the last trading day (Thursday, 30th Nov 2023), rising from $0.378 to $0.394.During the last trading day the stock fluctuated 6.38% from a day low at $0.371 to a day high of $0.395.The price has fallen in 6 of the last 10 days but is still up by 3.68% over the past 2 weeks. Volume fell on the …
12 Feb 2014 ... Executives and guests of Inovio Pharmaceuticals, Inc. will visit the New York Stock Exchange (NYSE) on Wednesday, Feb 12, 2014.
Find the latest Inovio Pharmaceuticals, Inc. (INO) stock quote, history, news and other vital information to help you with your stock trading and investing. Home. ... Q3 2023 Earnings Call Transcript November 9, 2023 Inovio Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.13 EPS, expectations were $-0.13 ...It's been a rough 12 months for Inovio Pharmaceuticals (INO-3.67%).In the past year, shares of the company have declined by 35% while the S&P 500 has risen 30%. The main reason for this abysmal ...Shares of Inovio Pharmaceuticals Inc. (INO) and Novavax Inc. (NVAX) took a hit on Wednesday as the companies failed to make it to the list of finalists for the Operation Warp Speed initiative. 2.Web21 Des 2021 ... Inovio Pharmaceuticals (INO) ... The shares have a poor EPS Rating of 18. This reflects INO stock's continuing losses per share. On Dec. 21, ...Inovio Pharmaceuticals is a biotechnology company that focuses on bringing to market ... certification on behalf of Inovio stock purchasers from February 14, 2020 ...At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Inovio Pharmaceuticals Inc. If you are looking for stocks with good return, Inovio Pharmaceuticals Inc stock can be a bad, high-risk 1-year investment option. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2023 Earnings Call Transcript November 9, 2023 Inovio Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.13 EPS ...From 1998 through today, Inovio Pharmaceuticals' stock history has been largely a depressing one. A quick analysis of Inovio Pharmaceuticals ' ( INO 2.77%) stock performance history shows plenty ...INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Commission (EC) has granted orphan drug designation for INO-3107, the company's product …Shares Outstanding: As of June 30, 2023, INOVIO had 268.1 million common shares outstanding and 290.0 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt.Inovio Pharmaceuticals. Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate ...
Future criteria checks 2/6. Inovio Pharmaceuticals is forecast to grow earnings and revenue by 36.7% and 80.4% per annum respectively while EPS is expected to grow by 46.7% per annum.Inovio Pharmaceuticals Inc INO Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability …Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2023 Earnings Call Transcript November 9, 2023 Inovio Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.13 EPS ...Instagram:https://instagram. consumer cyclical stocksfirst republick bank stockjngtxmicro cap stocks Nov 1, 2023 · The stock option has an exercise price of $0.36, the closing price of INOVIO's common stock on the Grant Date. The stock option will vest and become exercisable with respect to one-fourth of the shares underlying the stock option vested on the Grant Date, and an additional one-fourth of the shares underlying the stock option on the first ... banks that give virtual debit cardsishares ibonds etf Inovio Pharmaceuticals. Market Cap. $137M. Today's Change. (-3.25%) -$0.02. Current Price. $0.51. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium ...Web wton Inovio Pharmaceuticals ... There's not much real hope left with this stock, so I'd advise closing your Inovio position or removing it from your watchlist and not waiting for it to recover. 2.WebINOVIO's global Phase 3 efficacy trial receives authorization to proceed from Brazil; other countries to follow INOVIO to conduct INNOVATE Phase 3 efficacy trial with partner Advaccine in areas of world in need of COVID-19 vaccines INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA …Web